Supply Issues Becton Dickinson UK Ltd Venous Tube KFK374 (ICN 3474)

• The supply issue with the venous tube from Becton Dickinson UK is continuing.
• One product code remains subject to Protect Demand Management:
  • KFK374.
• KFK374 is available to order through NHS Supply Chain. However, trusts are allocated a maximum daily quantity or “threshold” to ensure fair supply of available stock across the NHS.
• See our Downloads ▼ section to access the product listing for further information on the affected product code and potential alternative and for a full list of product codes subject to Protect Demand Management.
• The supply issue is now anticipated to be resolved by 22 October 2026.

Change:

• The supplier Becton Dickinson UK Ltd has informed us of a supply issue with its venous tube.
• There is one product code affected:
  • KFK374 − Venous Tube Sodium Fluoride Potassium Oxalate.
• The supply issue is due to a delay in manufacturing causing shortage of stock.
• Due to this ongoing supply issue, the product is now being threshold managed and is subject to Protect Demand Management.

Impact:

• KFK374 is available to order through NHS Supply Chain. However, trusts are allocated a maximum daily quantity or “threshold” to ensure fair supply of available stock across the NHS.
• See our Downloads ▼ section to access the product listing for further information on the affected product code and potential alternative.
• The supply issue is anticipated to be resolved by 6 October 2026.

Next Steps:

• Customers are advised to log into our website to view the product listing for further information on the affected product code and potential alternative.  
• The continuing supply issue is being monitored in conjunction with the supplier, and we will continue to review the stock situation to minimise further disruption and update this ICN with the latest information as it becomes available.
• If you have any further questions, please contact your local NHS Supply Chain Customer Services Advisor.

Please note that due to the clinical nature of these alternative products, we advise you to consult your own clinical experts to ensure suitability for your organisations use of these products.